{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Blood samples were planned to be collected for assessment of Cmax.","groups":[{"description":"Participants received niraparib 300 mg (3×100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kg and Baseline platelet count \\>=150,000 per μL) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG000","title":"Niraparib"}],"populationDescription":"ITT Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.","reportingStatus":"POSTED","timeFrame":"Up to 34 months","title":"Peak Plasma Concentration (Cmax)","type":"OTHER_PRE_SPECIFIED"}